Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ultragenyx Pharmaceutical

35.06
-3.8100-9.80%
Post-market: 35.060.00000.00%19:59 EDT
Volume:1.32M
Turnover:47.11M
Market Cap:3.29B
PE:-5.58
High:38.39
Open:38.00
Low:34.96
Close:38.87
Loading ...

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
21 Dec 2024

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
21 Dec 2024

Wells Fargo Remains a Buy on Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
21 Dec 2024

Ultragenyx Pharma Is Maintained at Overweight by Wells Fargo

Dow Jones
·
20 Dec 2024

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

GlobeNewswire
·
20 Dec 2024

Ultragenyx Reports Patient Dosing in Angelman Syndrome Trial

MT Newswires Live
·
20 Dec 2024

BRIEF-Ultragenyx Announces First Patient Dosed In Pivotal Phase 3 Aspire Study Evaluating Gtx-102 In Angelman Syndrome

Reuters
·
20 Dec 2024

Ultragenyx Pharmaceutical Inc - Primary Endpoint Is Improvement in Cognition Assessed by Bayley-4

THOMSON REUTERS
·
20 Dec 2024

Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating Gtx-102 in Angelman Syndrome

THOMSON REUTERS
·
20 Dec 2024

Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome

GlobeNewswire
·
20 Dec 2024

Ultragenyx Seeks FDA Accelerated Approval for Gene Therapy to Treat Sanfilippo Syndrome

MT Newswires Live
·
19 Dec 2024

Ultragenyx submits BLA to FDA for UX111

TIPRANKS
·
19 Dec 2024

Ultragenyx Submits Biologics License Application to the U.S. FDA for Ux111 Aav Gene Therapy for the Treatment of Sanfilippo Syndrome Type a (Mps Iiia)

THOMSON REUTERS
·
19 Dec 2024

Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)

GlobeNewswire
·
19 Dec 2024

U.S. RESEARCH ROUNDUP- Domino's Pizza, Honeywell, Walmart

Reuters
·
17 Dec 2024

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Bicycle Therapeutics (BCYC) and Quest Diagnostics (DGX)

TIPRANKS
·
16 Dec 2024

Analysts Offer Insights on Healthcare Companies: Evolus (EOLS), Ultragenyx Pharmaceutical (RARE) and Henry Schein (HSIC)

TIPRANKS
·
16 Dec 2024

TD Cowen Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
11 Dec 2024

Ultragenyx (RARE) Down 6.8% Since Last Earnings Report: Can It Rebound?

Zacks
·
06 Dec 2024

Possible Bearish Signals With Ultragenyx Pharmaceutical Insiders Disposing Stock

Simply Wall St.
·
04 Dec 2024